Summit Partners Public Asset Management, LLC Krystal Biotech, Inc. Transaction History
Summit Partners Public Asset Management, LLC
- $4.13 Billion
- Q4 2024
A detailed history of Summit Partners Public Asset Management, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Summit Partners Public Asset Management, LLC holds 90,000 shares of KRYS stock, worth $15.9 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
90,000Holding current value
$15.9 Million% of portfolio
0.34%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding KRYS
# of Institutions
298Shares Held
24.3MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$695 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$507 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$463 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$225 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$155 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.52B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...